JP2017524143A - Ｄ−アミノ酸オキシダーゼ阻害剤としての既知の化合物の使用 - Google Patents

Ｄ−アミノ酸オキシダーゼ阻害剤としての既知の化合物の使用 Download PDF

Info

Publication number
JP2017524143A
JP2017524143A JP2017510438A JP2017510438A JP2017524143A JP 2017524143 A JP2017524143 A JP 2017524143A JP 2017510438 A JP2017510438 A JP 2017510438A JP 2017510438 A JP2017510438 A JP 2017510438A JP 2017524143 A JP2017524143 A JP 2017524143A
Authority
JP
Japan
Prior art keywords
schizophrenia
daao
disease
drugs
omeprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017510438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524143A5 (https=
Inventor
ユーフェン ジェーン ツェン
ユーフェン ジェーン ツェン
ユ−リ リウ
ユ−リ リウ
チュン−ミン サン
チュン−ミン サン
ハイ−グォ フ
ハイ−グォ フ
チ−ミン リウ
チ−ミン リウ
ウェン−スン ライ
ウェン−スン ライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of JP2017524143A publication Critical patent/JP2017524143A/ja
Publication of JP2017524143A5 publication Critical patent/JP2017524143A5/ja
Priority to JP2020035496A priority Critical patent/JP6941326B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03003—D-Amino-acid oxidase (1.4.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G01N2333/90644—D-Amino acid oxidase (1.4.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Library & Information Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
JP2017510438A 2014-04-30 2015-04-30 Ｄ−アミノ酸オキシダーゼ阻害剤としての既知の化合物の使用 Pending JP2017524143A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020035496A JP6941326B2 (ja) 2014-04-30 2020-03-03 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986480P 2014-04-30 2014-04-30
US61/986,480 2014-04-30
PCT/US2015/028385 WO2015168346A1 (en) 2014-04-30 2015-04-30 Use of known compounds as d-amino acid oxidase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035496A Division JP6941326B2 (ja) 2014-04-30 2020-03-03 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための医薬組成物

Publications (2)

Publication Number Publication Date
JP2017524143A true JP2017524143A (ja) 2017-08-24
JP2017524143A5 JP2017524143A5 (https=) 2018-06-14

Family

ID=54359315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017510438A Pending JP2017524143A (ja) 2014-04-30 2015-04-30 Ｄ−アミノ酸オキシダーゼ阻害剤としての既知の化合物の使用
JP2020035496A Active JP6941326B2 (ja) 2014-04-30 2020-03-03 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020035496A Active JP6941326B2 (ja) 2014-04-30 2020-03-03 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための医薬組成物

Country Status (15)

Country Link
US (2) US9868975B2 (https=)
EP (2) EP3498275B1 (https=)
JP (2) JP2017524143A (https=)
KR (2) KR102537686B1 (https=)
CN (2) CN112773798B (https=)
AU (1) AU2015253099B2 (https=)
CA (1) CA2946153C (https=)
DK (1) DK3137658T3 (https=)
ES (2) ES2951736T3 (https=)
IL (1) IL248567B (https=)
MX (2) MX2016011551A (https=)
PT (1) PT3137658T (https=)
SG (2) SG11201607166XA (https=)
TW (1) TWI675660B (https=)
WO (1) WO2015168346A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020112558A (ja) * 2014-04-30 2020-07-27 ユーフェン ジェーン ツェン 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための薬物
JP2023003411A (ja) * 2021-06-23 2023-01-11 ヨーダ ファーマシューティカルズ インコーポレーテッド Ｎｌｒｐ３によって媒介される疾患及び障害の治療及び／又は予防のためのベンゾイミダゾール誘導体
JP2025001668A (ja) * 2019-01-23 2025-01-08 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Ｎｍｄａ、グリシンおよびａｍｐａ受容体のモジュレーターの薬理ゲノミクス決定支援

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3512840B1 (en) * 2016-09-14 2024-03-06 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
CN108143734A (zh) * 2018-02-09 2018-06-12 南京中医药大学 阿莫地喹及其药学上可接受的盐在制备用于治疗阿尔茨海默病的药物中的应用
US20220016099A1 (en) * 2018-12-06 2022-01-20 Trinuero Benzimidazole or benzoxazole derivatives for preventing and treating central nervous system disease, diabetes, and complications thereof
CN110297839B (zh) * 2019-06-25 2022-04-12 中国人民解放军军事科学院军事医学研究院 药物适应症的查询方法、装置、计算机设备和存储介质

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018180A1 (en) * 1995-11-13 1997-05-22 Akiko Itai Design method of physiologically active compound
JP2009539764A (ja) * 2006-05-10 2009-11-19 ラクリード、インコーポレイテッド 肺の疾患の酵素的処置のための組成物及び方法
WO2013027000A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as daao inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619652A (en) 1982-12-23 1986-10-28 Alza Corporation Dosage form for use in a body mounted pump
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
GB9208492D0 (en) 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9304500D0 (en) 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
US20030162825A1 (en) 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
CA2559105A1 (en) 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Benzisoxazoles
DE602005013372D1 (de) * 2005-07-29 2009-04-30 Rottapharm Spa Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten
US20090306169A1 (en) * 2005-10-06 2009-12-10 Brandish Philip E Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors
US7960544B2 (en) * 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
EP2057162A2 (en) 2006-06-30 2009-05-13 Sepracor Inc. Fused heterocyclic inhibitors of d-amino acid oxidase
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
MX2010013247A (es) 2008-06-02 2011-02-23 Ironwood Pharmaceuticals Inc Derivados de acido carboxilico selenazol y selenofeno.
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
KR101348984B1 (ko) * 2012-01-31 2014-01-10 전남대학교산학협력단 박테리아 시토크롬 ｐ450을 이용한 오메프라졸로부터 대사산물의 신규한 생산방법 및 이를 위한 조성물
PT3137658T (pt) * 2014-04-30 2022-05-05 Univ Nat Taiwan Uso de compostos conhecidos como inibidores do d-aminoácido oxidase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018180A1 (en) * 1995-11-13 1997-05-22 Akiko Itai Design method of physiologically active compound
JP2009539764A (ja) * 2006-05-10 2009-11-19 ラクリード、インコーポレイテッド 肺の疾患の酵素的処置のための組成物及び方法
WO2013027000A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as daao inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASUMI KATANE, NAOKO OSAKA, SATSUKI MATSUDA, KAZUHIRO MAEDA, ET AL: "IDENTIFICATION OF NOVEL D-AMINO ACID OXIDASE INHIBITORS BY IN SILICO SCREENING AND THEIR FUNCTIONAL", J. MED. CHEM., vol. V56 N5, JPN5017003296, 7 February 2013 (2013-02-07), pages 1894 - 1907, ISSN: 0004290236 *
PAUL A. NOVICK; OSCAR F. ORTIZ; JARED POELMAN; ET AL: "SWEETLEAD: AN IN SILICO DATABASE OF APPROVED DRUGS, REGULATED CHEMICALS, AND HERBAL ISOLATES FOR COM", PLOS ONE, vol. V8 N11, JPN5017003298, November 2013 (2013-11-01), pages 79568 - 1, ISSN: 0004290237 *
TIM SPAREY ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 11, JPN6019002422, 1 June 2008 (2008-06-01), pages 3386 - 3391, ISSN: 0004165879 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020112558A (ja) * 2014-04-30 2020-07-27 ユーフェン ジェーン ツェン 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための薬物
JP2025001668A (ja) * 2019-01-23 2025-01-08 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Ｎｍｄａ、グリシンおよびａｍｐａ受容体のモジュレーターの薬理ゲノミクス決定支援
JP2023003411A (ja) * 2021-06-23 2023-01-11 ヨーダ ファーマシューティカルズ インコーポレーテッド Ｎｌｒｐ３によって媒介される疾患及び障害の治療及び／又は予防のためのベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
JP6941326B2 (ja) 2021-09-29
ES2951736T3 (es) 2023-10-24
SG10202102125SA (en) 2021-04-29
TWI675660B (zh) 2019-11-01
USRE49340E1 (en) 2022-12-20
CA2946153C (en) 2022-06-14
AU2015253099A1 (en) 2016-09-15
CN106687626B (zh) 2021-01-26
DK3137658T3 (da) 2022-05-02
TW201610246A (zh) 2016-03-16
EP3498275C0 (en) 2023-06-07
EP3137658A4 (en) 2018-03-14
MX2016011551A (es) 2017-02-28
US20170037448A1 (en) 2017-02-09
JP2020112558A (ja) 2020-07-27
AU2015253099B2 (en) 2019-07-18
EP3137658A1 (en) 2017-03-08
MX2021000133A (es) 2021-03-25
IL248567A0 (en) 2016-12-29
CA2946153A1 (en) 2015-11-05
WO2015168346A1 (en) 2015-11-05
NZ723652A (en) 2021-04-30
US9868975B2 (en) 2018-01-16
KR102537686B1 (ko) 2023-05-30
KR20160147868A (ko) 2016-12-23
SG11201607166XA (en) 2016-09-29
EP3137658B1 (en) 2022-03-30
CN106687626A (zh) 2017-05-17
EP3498275B1 (en) 2023-06-07
IL248567B (en) 2022-08-01
EP3498275A1 (en) 2019-06-19
CN112773798B (zh) 2024-03-29
KR20220123738A (ko) 2022-09-08
ES2911879T3 (es) 2022-05-23
CN112773798A (zh) 2021-05-11
PT3137658T (pt) 2022-05-05

Similar Documents

Publication Publication Date Title
JP6941326B2 (ja) 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための医薬組成物
Wu et al. Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor
US20190167676A1 (en) Methods for improving resistance to skeletal muscle fatigue
Hashimoto Glycine transport inhibitors for the treatment of schizophrenia
KR101825972B1 (ko) 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합
KR20170012449A (ko) 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도
EP2680849A2 (en) 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
Hellyer et al. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation
JP2014514259A (ja) 疼痛および他の障害の処置のための化合物および方法
CN110520418B (zh) Ampa受体增强剂
JP5466510B2 (ja) シドノンイミン−特異的ドーパミン再摂取阻害剤およびそのドーパミン関連障害の治療における使用
HK40042967A (en) Use of known compounds as d-amino acid oxidase inhibitors
HK40042967B (zh) 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
HK1233313B (zh) 作為d-氨基酸氧化酶抑制劑的已知化合物的用途
HK1233313A1 (en) Use of known compounds as d-amino acid oxidase inhibitors
NZ723652B2 (en) Use of known compounds as d-amino acid oxidase inhibitors
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
Lackovic et al. Pharmacological characterization and preclinical evaluation of 11h: a novel, brain-penetrant PDE4 inhibitor for neurological disorders
KR20190032598A (ko) 히스타민-3 수용체 역효능제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
US20110294835A1 (en) Muscarinic Agonists as Cognitive Enhancers
Ofori Tetrahydroisoquinoline and 1-(pyridin-2-Yl) piperazine as Multi-Receptor Probes for CNS Drug Design
EA039381B1 (ru) Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения
JP2015166385A (ja) 疼痛および他の障害の処置のための化合物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200623